Immunosuppression and Growth Factors for Severe Aplastic Anemia: New Data for Old Questions |
May 2020 |
Haematologica |
Aplastic Anemia |
Myelodysplastic Syndromes: Moving Towards Personalized Management |
May 2020 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria |
Aug 2023 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag |
Apr 2021 |
Haematologica |
Aplastic Anemia |
Is blood transfusion safe during the COVID-19 pandemic? |
Sep 2020 |
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
Jan 2021 |
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
Targeting the Microenvironment in MDS: The Final Frontier |
Jul 2020 |
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes |
May 2023 |
Frontiers in Oncology |
Aplastic Anemia |
Novel therapeutic choices in immune aplastic anemia |
Sep 2020 |
F1000Research |
Aplastic Anemia |
Getting personal with myelodysplastic syndromes: is now the right time? |
Apr 2019 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |